Detail
| LncRNA Name | lincRNA-p21 |
| Synonyms | TP53COR1, linc-p21, lincRNA-p21 |
| Region | NA Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot |
| Sample | cell lines (DU145 and LNCaP) |
| Expression Pattern | down-regulated |
| Function Description | lincRNA-p21 silencing in DU145 and LNCaP cells induced up-regulation of PKM2 and activation of glycolysis, which could be reversed by PKM2 knockdown or rapamycin treatment.the proliferation and tumorigenesis of lincRNA-p21-silenced prostate cancer cells were significantly inhibited after knocking down PKM2. 3-bromopyruvate (3-Brpa) or rapamycin treatment largely decreased the tumour burden. PKM2 expression was inversely correlated with the lincRNA-p21 level and the survival of prostate cancer patients. |
| Pubmed ID | 28994148 |
| Year | 2017 |
| Title | LincRNA-p21 suppresses development of human prostate cancer through inhibition of PKM2. |
| External Links |
| Links for lincRNA-p21 | GenBank HGNC lncrnadb Noncode |
| Links for prostate cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.